Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Filings indexed 950 across all filing types
Latest filing 2023-10-03 Director's Dealing
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-10-03 English
Director's Dealing 2023
Director's Dealing
2023-10-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-09-15 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-09-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated September 12, 2023. The key content is the announcement of the appointment of a new Chairman of the Board and the retirement of the previous Chairman, along with details of compensation arrangements. This clearly relates to changes in the company's board of directors. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy solicitation or voting results announcement. It is not a report publication announcement or regulatory filing of a different nature. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4636 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Confidence is high given the clear content and form type.
2023-09-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.